Tenax Therapeutics, Inc - TENX Company Cash Volume

Tenax Therapeutics is developing cardiology drugs under strict FDA supervision and robust patent protection. The current cash balance demonstrates financial stability, while 0.12 represents the latest level value. Business revenues rely on insurance fund procurement, and the research-oriented management is successfully adapting Phase III trial protocols for the key product.
Analytical breakdowns and data insights for company Tenax Therapeutics, Inc. (TENX)

This indicator assesses solvency and default risk by tracking the volume of liquid assets available to cover current liabilities. The cash balance trend for Tenax Therapeutics (TENX) on the GURU.Markets platform reflects the burn rate of reserves, which is critical for Tenax Therapeutics, where Christopher Kenyon's scientific discipline ensures that funding strictly aligns with the clinical trial schedule for pulmonary hypertension drugs.